

INITIAL MUTATIONS DIRECT ALTERNATIVE PATHWAYS OF PROTEIN EVOLUTION

Merijn L.M. Salverda^{a, 1}, Eynat Dellus^b, Florian A. Gorter^a, Alfons J.M. Debets^a, John van der Oost^c, Rolf F. Hoekstra^a, Dan S. Tawfik^b and J. Arjan G.M. de Visser^a

^aLaboratory of Genetics, Department of Plant Sciences, Wageningen University, P.O.Box 309, 6700 AH Wageningen, the Netherlands; ^bDepartment of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel; ^cLaboratory of Microbiology, Department of Agrotechnology and Food Sciences, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, the Netherlands

¹To whom correspondence may be addressed. E-mail: merijnsalverda@hotmail.com, phone: +31 317 483142, fax: +31 317 483146

ABSTRACT

Whether evolution is erratic due to random historical details, or is repeatedly directed along similar paths by certain constraints, remains unclear. Epistasis (i.e. non-additive interactions between mutations that affect fitness) is a mechanism that can contribute to both scenarios. Epistasis can constrain the type and order of selected mutations, but it can also make adaptive trajectories contingent upon the first random substitution. This effect is particularly strong under sign epistasis, when the sign of the fitness effects of a mutation depends on its genetic background.

In the current study, we examine how epistatic interactions between mutations determine alternative evolutionary pathways, using *in vitro* evolution of the antibiotic resistance enzyme TEM-1 β -lactamase. First, we describe the diversity of adaptive pathways among replicate lines during evolution for resistance to a novel antibiotic (cefotaxime). Consistent with the prediction of epistatic constraints, most lines increased resistance by acquiring three mutations in a fixed order. However, a few lines deviated from this pattern. Next, to test whether negative interactions between alternative initial substitutions drive this divergence, alleles containing initial substitutions from the deviating lines were evolved under identical conditions. Indeed, these alternative initial substitutions consistently led to lower adaptive peaks, involving more and other substitutions than those observed in the common pathway. We found that a combination of decreased enzymatic activity and lower folding cooperativity underlie negative sign epistasis in the clash between key mutations in the common and deviating lines (Gly238Ser and Arg164Ser, respectively).

Our results demonstrate that epistasis contributes to contingency in protein evolution by amplifying the selective consequences of random mutations.

Author summary

A long-term goal of evolutionary biology is to understand the factors that govern the outcome of evolution. Epistasis (i.e. the situation in which the fitness effect of a mutation depends on its genetic background) is one such factor. Epistasis not only affects the dynamics of evolution, it may also direct its outcome by affecting the type and order of selected mutations. This effect is particularly strong under sign epistasis, which occurs when the sign of a mutation's fitness effect depends on its genetic background. Here, we demonstrate how epistasis causes divergence of mutational pathways of an antibiotic resistance enzyme, TEM-1 β -lactamase. First, we use *in vitro* mutagenesis followed by selection for cefotaxime resistance to demonstrate that alternative mutational pathways towards highly resistant variants exist in addition to the main pathway that was previously described. Next, to test whether negative interactions between alternative initial substitutions govern this diversification, we start identical evolution experiments with alleles containing initial substitutions from the deviating lines. These alleles consistently evolve to lower adaptive peaks and acquire different mutations than those in the main pathway. Our results demonstrate that sign epistasis between alternative initial substitutions may force evolution to follow different mutational pathways.

Introduction

Understanding the factors that determine the outcome of evolution is a long-term goal of evolutionary biology. Epistasis (i.e. non-additive interactions between mutations that affect fitness) is one such determinant. Epistasis can affect the type and order of mutations that can be fixed by natural selection [1,2]. As a result, it affects the dynamics of evolution, for instance by causing a mutation to have smaller fitness benefits in the presence than in the absence of other mutations [3,4]. Under a specific type of epistasis called sign epistasis, interactions affect not only the size, but also the *sign* of the fitness effect of mutations [5]. Sign epistasis introduces particularly strong evolutionary constraints, and may create fitness landscapes with multiple adaptive peaks isolated by valleys of lower fitness [5,6]. In such rugged fitness landscapes, epistasis can theoretically cause entire mutational pathways to be contingent on the chance occurrence of initial mutations due to a combination of two effects. First, once an initial mutation is fixed, epistasis prevents the selection of alternative initial substitutions. Next, it concurrently facilitates the selection of mutations that are beneficial in the background of this particular initial substitution, but that may be detrimental (or less beneficial) in the background of alternative initial substitutions.

The predicted evolutionary constraints stemming from epistasis also depend on the available genetic variation. For example, a population that is stuck on a suboptimal adaptive peak can escape from this peak and cross the surrounding fitness valley when mutants carrying useful combinations of mutations can be produced. This may be expected to occur in large populations with a high mutation rate [7], or possibly when there is recombination [8,9]. For asexual populations, the evolutionary constraints determined by epistasis are the most pronounced when the supply of mutations is low and mutations arise

and go to fixation one at a time. In this case, even the smallest fitness valleys form obstacles for natural selection.

To demonstrate how epistatic constraints affect evolution, one would ideally need to observe the full sequence of mutational events and subsequently test the evolutionary consequences of specific mutational interactions. While sequence divergence data may be used to study the role of epistasis [10], experimental evolution with microbes (where replicate lines evolve under identical conditions) offers a powerful experimental methodology. Such studies have shown instances of both divergent and parallel evolution, including changes in fitness, cell size and genotype [11-16]. A remarkable case of historical contingency was recently reported in a long-term evolution experiment with *Escherichia coli*, when investigators found that after more than 30,000 generations, multiple ‘potentiating’ mutations allowed one of twelve populations to evolve a key metabolic innovation [17]. Despite of such findings, identifying the exact order of mutations, and testing their individual and combined fitness effects has been challenging even with simple organisms.

Here, we used *in vitro* evolution of an antibiotic resistance enzyme to study the effect of epistasis on the process of mutational pathway diversification. We used TEM-1 β -lactamase, an enzyme that catalyzes the hydrolysis of ampicillin, and studied its evolution towards increased activity against the semi-synthetic antibiotic cefotaxime. Briefly, we introduced random mutations using error-prone PCR and selected mutant alleles that mediate bacterial growth in a gradient of cefotaxime concentrations. After each round of evolution, a fixed mutant allele from each line was isolated from the highest antibiotic concentration in which bacterial growth was observed. This system offers the opportunity

to study entire adaptive pathways at the level of phenotype (i.e. antibiotic resistance) and genotype. Previous studies used the same system to develop protocols for directed evolution [18], to investigate evolutionary scenarios [19,20] and to explore the potential of evolution of resistance to a range of β -lactam antibiotics [21,22]. Collectively, these studies showed the contribution of both unique and repetitive substitutions to TEM-1's adaptation. They also identified a five-fold mutant (containing a promoter mutation and substitutions A42G, E104K, M182T and G238S) with an extremely high cefotaxime resistance [18,23,24]. Measurement of the resistance of constructed mutants carrying subsets of these mutations revealed substantial sign epistasis [24-26] and predicted the inaccessibility of most mutational pathways towards the five-fold mutant [24]. Notably, several other mutations in addition to the five mentioned above are capable of increasing cefotaxime resistance, independently or in combination with other substitutions [25,26]. We were therefore interested in assessing whether evolution allowing all possible mutations would always lead to the fivefold mutant or whether alternative pathways to cefotaxime resistance exist, and to what extent epistasis plays a role in this.

Results

Diversity of mutational pathways. Twelve replicate lines of the TEM-1 gene were subjected to three rounds of error-prone PCR followed by selection for increased cefotaxime resistance. To broadly explore existing adaptive pathways, we varied the mutation rate (~ 2 and ~ 6 nucleotide substitutions per amplicon per PCR, see Text S1) and introduced a simplified form of recombination in half of the lines (see Material and Methods), although neither of these two treatments appeared to affect the final level of

adaptation, as measured by increases of the minimal inhibitory concentration (MIC) for cefotaxime (mutation rate: Mann-Whitney $U = 12$, two-tailed $P = 0.394$; recombination: $U = 12$, $P = 0.394$). After each round of evolution, a single clone was picked from the highest cefotaxime concentration that still permitted growth. We used this type of bottleneck selection via the fixation of a single clone [19], because it allowed us to follow the mutational pathway of the evolving genotypes. In addition, sequencing indicated that the evolved populations were dominated by a single clone (see text S1). Plasmid from this clone was purified and used as the template for the next round of evolution. Selected alleles were sequenced and assayed for increased cefotaxime resistance by measuring the MIC after recloning into the original vector and retransformation into naïve bacterial cells.

Figure 1A shows the changes in MIC for all lines, which levels off after the second round of evolution, suggesting the approach of one or more fitness peaks. This pattern is mirrored in the number of amino acid substitutions recorded per round for the twelve lines (30 substitutions after the first round, 29 after the second round, and 8 after the third, see Table S2). The amino acid substitutions show a remarkable pattern of parallel response. Seven of the 12 lines contained the same three substitutions, with G238S always occurring in the first round, often together with M182T, followed by E104K in the second round (see Table 1 for overview, details and silent mutations for Tables 1-4 can be found in Table S1). Since the promoter region was not allowed to evolve in our experiments, these alleles differ from the previously described adaptive peak in the absence of A42G. There is evidence that A42G is a so-called ‘global suppressor’ substitution [27] and since many such substitutions with similar functional effects exist [28,29], we suspect that in our experiments A42G is sometimes replaced by other global suppressor substitutions (e.g. H153L in line 1 of Table

1). We can not explain the absence of A42G in the lines that contain E104K, M182T and G238S after two rounds of evolution and remain unchanged after the third round (lines 5, 9 and 10 in Table 1). However, we would like to point out that the combination of E104K, M182T, and G238S has occasionally been reported as the evolutionary end point in other studies [26,30]. Overall, the striking pattern of parallel evolution is consistent with adaptive constraints from epistasis. Five lines (numbers 3, 4, 7, 11 and 12) deviate from this pattern, because they lack one or more of the three parallel substitutions and evolve to lower resistance levels (Mann-Whitney, $U = 1$, one-tailed $P = 0.003$).

Epistasis between initial substitutions creates alternative adaptive pathways. We were interested in testing to what extent epistasis between different initial substitutions determined the mutational pathways taken. To test this effect of epistasis, we first had to identify the initial mutations of the common and deviating pathways. Substitution G238S was found in 10 lines after the first round of evolution and is known to cause the greatest increase in cefotaxime resistance among all known single TEM-1 mutations [23-25]. We therefore screened the two lines that lack G238S (lines 3 and 4) for first-round adaptive substitutions with possible negative epistatic interactions with G238S, and found a likely candidate in both lines. Substitution R164S in line 3 has a positive effect on cefotaxime MIC, but shows a lower MIC when combined with G238S than both substitutions alone (see [25] and Table 5). Similarly, substitution A237T in line 4 increases activity on cefotaxime [31] and frequently occurs in clinical isolates, but never in combination with G238S (<http://www.lahey.org/studies/temtable.asp>). In our experiments, the MIC of the double mutant A237T/ G238S was equal to that of A237T alone and only slightly higher

than that of TEM-1, but considerably lower than that of G238S, thus confirming negative epistasis (see Table S3).

To test the predicted contingent role of these initial mutations, we ran another set of evolution experiments, this time starting with TEM-1 alleles carrying either R164S or A237T. We expected that these mutations would prevent the selection of mutations found in the common pathway, and instead facilitate the selection of other mutations. Five replicate lines of each allele were allowed to adapt to cefotaxime as before, using a mutation rate of ~ 3 mutations per amplicon (see Text S1 and Table S4). Figure 1B shows the average change in resistance for all 10 new lines, as well as the average for the 12 lines from the previous experiment. Again, MIC values levelled off after an initial rise, suggesting that the new lines also approach one or more adaptive peaks. However, despite their head start due to the introduced adaptive mutation, after three rounds of evolution the resistance of these lines was significantly lower than that reached by the ten G238S-containing lines in the previous experiment (for both R164S and A237T lines: $U = 3$, one-tailed $P < 0.01$), while not significantly different from each other ($U = 12$, two-tailed $P = 1$). The phenotypic assays, therefore, suggest that R164S and A237T force evolution to take different adaptive trajectories than the common trajectory followed by the TEM-1 lines.

The amino acid substitutions found in the new lines confirm this conclusion (see Table 2). First, despite their lower final level of resistance and lower average mutation rate, the five R164S lines accumulated more mutations than the ten G238S lines of the previous experiment (7.2 mutations, without the introduced R164S, versus 4.7 mutations including G238S, $U = 4.5$, one-tailed $P = 0.008$). Second, mutations in the background of R164S and A237T occurred at different positions, with relatively more mutations in the functionally

important omega-loop (see Figure S1) compared to the ten lines carrying substitution G238S (Chi-square = 8.80, d.f. = 1, $P < 0.01$), suggesting alternative routes towards the new enzyme functionality. Third, the presence of substitution R164S or A237T prevented the selection of G238S in all lines (Fisher's exact test, $P < 0.001$), and often prevented the selection of other mutations repeatedly found in the G238S background, while they facilitated the selection of other mutations. For example, E104K is more often selected when G238S is present than when R164S ($P = 0.004$) or A237T ($P = 0.001$) are present, while E240K is more often found in the background of R164S than with G238S ($P = 0.004$). Other parallel substitutions, such as M182T, show a weaker association (i.e. with G238S compared to R164S, $P = 0.036$), and appear beneficial in more backgrounds. Together, the observed changes in phenotype and genotype show that the introduced substitutions are responsible for the pattern of parallel and divergent adaptation: they facilitate the selection of certain mutations, while preventing the selection of others.

Effect of epistasis between non-initial mutations. We have described the effect of epistasis between initial mutations on mutational trajectories. We were interested to see how pervasive such epistatic interactions were and whether they continue to play a role once the first mutational step in a mutational trajectory has been taken. With this in mind, our attention was drawn to line 7 of Table 1. Like lines 3 and 4, line 7 deviates from the other lines in Table 1 in that it lacks two of the three main substitutions E104K, M182T, and G238S: it does contain G238S, but lacks both E104K and M182T. Because G238S is present in line 7 after the first round of evolution, we assumed that either A184V or R191H, the other two substitutions found after the first round, might be responsible for the atypical

mutational pathway of this line. Because we had observed the combination of A184V and G238S in pilot experiments and because A184V is physically very close to M182T, we suspected that this substitution might be a functional equivalent of M182T. To investigate whether the double mutant A184V/G238S would prevent other substitutions of the G238S-based pathway from occurring, we constructed a TEM-1 allele carrying these two substitutions. The MIC of this double mutant was indeed higher than that of G238S by itself (see Table S3). Next, we subjected the A184V/G238S allele to three rounds of error-prone PCR and selection for increased cefotaxime resistance, again with fivefold replication, a mutation rate of on average ~ 2 mutations per amplicon per error-prone PCR and without recombination. The amino acid substitutions and MIC-values recorded after each round of evolution and selection can be found in Table 3. Again, the MIC increases after the 1st and 2nd round, while it levels off in the 3rd round. Despite of the head start of the two introduced mutations, final MIC levels were significantly lower than those of the seven lines in Table 1 that contain mutations M182T and G238S ($U = 0$, one-tailed $P = 0.003$). The presence of A184V in the background of G238S prevented the selection of M182T (Fisher's exact test on all 13 lines of Tables 1 and 3 that contain M182T or A184V in combination with G238S: $P = 0.001$), but E104K was selected also in this background ($P = 0.07$).

More indications for sign epistatic interactions can be found in Tables 1-4. For example, substitutions E104K and E240K can be found in most lines, but never co-occur in the same line. Similarly, five out of six lines that contain T265M lack M182T, and it has been speculated that both substitutions have a similar (i.e. stabilizing) function [32]. We lack statistical power to test more interactions due to their low incidence, but our examples

show that sign epistasis in TEM-1 is pervasive and has adaptive consequences not only for the first, but also for later steps of the mutational pathway of this enzyme.

Adaptive constraints from pairs of epistatic mutations. Next, we were interested in testing the strength of the adaptive constraints resulting from sign epistasis directly by allowing alleles containing combinations of negatively interacting mutations to evolve. When evolution starts from an allele containing two negatively interacting mutations, can it alleviate this negative interaction by the addition of other mutations, or can it only proceed by the reversion of one of these mutations? Also, does the strength of sign epistasis affect the strength of the adaptive constraint, such that stronger sign epistasis limits the adaptive alternatives? To test this, the negatively interacting R164S/G238S double mutant, exhibiting a strong negative interaction (see MIC values for cefotaxime in Table 5), and A237T/G238S, exhibiting weaker epistasis (see Table S3), were created by site directed mutagenesis, and subjected to three rounds of directed evolution as before. The MIC trajectories of the five lines started by both double mutants show great similarity to those of the 12 TEM-1 lines in the first experiment, except that they have lower MIC-values after the first round of evolution (Figure 1B; relative number of MIC doublings after round 1, $U = 9$, one-tailed $P < 0.001$).

For the A237T/G238S double mutant, only one line reverted A237T after the second round, while the other four retained the introduced mutations at residues 237 and 238 (see Table 4). Interestingly, the line that reverted A237T is the line that ended up having the highest MIC. Three of the lines that contained both A237T and G238S after three rounds of evolution did not acquire new substitutions in the third round. Lack of

reversion is unlikely to be an effect of the mutagenesis protocol, since the a(t) → g(c) transition that can revert both A237T and G238S, is relatively frequent in the mutational spectrum of the mutagenic polymerase we applied. It could be that these lines have gathered mutations in round one and two that have neutralized the negative interaction between G238S and A237T and hence made the reversions T237A and S238G either neutral or detrimental.

The combination of R164S and G238S seems to constrain evolution more severely, since all five lines eventually reverted R164S, and four lines did so directly after the first round of evolution (Table 4). One line gathered other mutations and increased MIC during the first two rounds of evolution, and reverted R164S after the third round. In this line, in both first two rounds, at least one mutation was incorporated that is known to be beneficial in both the R164S and G238S backgrounds (E240K [33] and M182T [26] respectively). Yet, the reversion S164R in the third round, combined with other mutations, resulted in a large increase in resistance, while that of most lines with a first round reversion levelled off at this point. Thus, the level of selective constraint caused by epistasis varies for different combinations of mutations, and correlates with the strength of the negative epistatic interaction for these two cases.

Analysis of the R164S/G238S double mutant. To gain insights into the biochemical basis of the sign epistatic interaction between R164S and G238S, we purified the double mutant, and the corresponding single mutants, and examined their kinetic parameters and stability (see Tables 5, S2 and S3). On ampicillin, the single mutants and double mutants exhibit very similar catalytic efficiency (k_{cat}/K_M). However, the double mutant exhibited much

lower k_{cat} than both single mutants, in particular relative to R164S, thus accounting for the lower MIC on ampicillin at concentrations above the K_M . The kinetic parameters of the double mutant on cefotaxime are essentially identical to that of the single mutant R164S, but 28-fold lower in terms of k_{act}/K_M than G238S. These differences correlate with the differences in the resistance *in vivo* (Table 5), but do not account for the observation that the double mutant exhibits MIC values that are lower than the R164S mutant, and are only slightly above TEM-1 itself. Thus, regarding the kinetic parameters, we observed epistasis between mutations R164S and G238S with respect to cefotaxime hydrolysis: the R164S mutation eliminates the much more beneficial effects of G238S. However, the kinetic parameters do not account for the sign epistasis observed for the resistance levels *in vivo*. The origin of the latter is likely to be lower levels of functional enzyme, which may result from the lower kinetic stability of the double mutant. The T_m -values of all three mutants are similar, and are lower than that of TEM-1. Thus the thermostability of both single mutants seems comparable to that of the double mutant. However, the double mutant exhibits a cooperativity factor (m value) that is ~2.5-fold lower than that of the two single mutants. In fact, the fit of the double mutant to the standard two-state unfolding model is poor (see Figure S2), also indicating that its folding follows a different path than that of wild-type TEM-1 and of the single mutants. Altogether, the similarity in k_{cat} and K_M values versus the lower MIC, and the perturbed folding parameters, suggest that sign epistasis relates to a combination of kinetic parameters that are much lower for the double mutant than for G238S on its own, and lower levels of properly folded and functional enzyme.

Discussion

We used laboratory evolution experiments with a model enzyme to study the topography of its fitness landscape by testing the involvement of epistasis in creating alternative mutational pathways. A previous reconstruction of the fitness landscape of TEM-1 β -lactamase for adaptation to cefotaxime based on MIC assays of all possible combinations of mutations A42G, E104K, M182T, G238S, and a promoter mutation suggested that, despite local ruggedness, it contains a single adaptive peak [24]. However, by allowing all possible mutations that may contribute to the evolution of cefotaxime resistance to be selected, we found that the fitness landscape contains more than a single adaptive peak. Our ability to monitor and manipulate the sequence of genetic changes allowed us to demonstrate that epistasis was at the basis of the landscape's ruggedness. Epistasis caused one pathway to be used preferentially, while making the particular choice of pathways historically contingent upon the first mutational step. This first step therefore resembles the crucial choice of lanes before a junction of alternative evolutionary routes. Finally, by studying how the biochemical and biophysical parameters for a specific pair of mutations correlate with the level of fitness (here, antibiotic resistance), we found that sign epistasis resulted from a combination of negative interactions at the level of enzyme activity and reduced folding efficiency (kinetic stability).

The epistatic constraints observed in our experiments depend not only on the topography of the fitness landscape, but also on the mutation supply rates of the evolving populations (i.e. population size \times mutation rate). The conditions in our experiments were such that mutation supply rates were in the order of 10^6 (i.e. library sizes of $\sim 6 \times 10^5$ and mutation rates of ~ 3 for most experiments) and multiple mutations were often selected in a single round of evolution (see Table 1). Assuming no mutational bias, simulations using the

PEDEL program [34] indicate that all possible 2581 single mutants (i.e. 861 nucleotides x 3 possible mutations) were present in our libraries, as well as up to 10% of all possible double mutants. That two of the 12 lines in our first experiment showed a deviating pattern of substitutions already after the first round of evolution, therefore, must be seen as a consequence of epistasis combined with clonal interference between genotypes carrying different sets of mutations – consistent with the fact that most lines (including the deviating lines) fixed multiple mutations. While epistatic constraints may be most severe during evolution by single-mutation selection (the so-called ‘weak-mutation, strong-selection’ regime), our results show that significant constraints are experienced also during evolution with much higher mutation supplies. Because of the high mutation supplies in our experiments, in some lines combinations of mutations that are individually neutral or deleterious but beneficial in combination may have been selected. The relative strength of the epistatic constraints experienced at different scales in genotype space will depend on the topography of the fitness landscape, and should be addressed in future work.

How important are our observations on a single enzyme for real organisms? In our case where mutations affect a single enzyme, sign epistasis results from the biophysical constraints underlying functionality of a single protein [35,36]. Although possibly less severe, similar constraints are likely to exist when mutations affect different genes and functions [37,38]. Differences observed in the molecular changes in two bacteriophage populations that evolved in parallel, indicate that mutational stochasticity and mutational order may influence the pattern of adaptation [11]. A recent analysis of epistasis between individually deleterious mutations affecting different genes of the fungus *Aspergillus niger* confirms the significance of sign epistasis for entire organisms [8]. Such epistatic

interactions can make evolution contingent by amplifying the effects of mutational chance events in finite populations, as demonstrated here. However, our results also show that even contingent evolution may have a relatively deterministic structure once the first step has been determined.

Materials and Methods

Strains and plasmids. *Escherichia coli* strain DH5 α E (Invitrogen) was used as a host for all plasmids. Plasmid pACSE3 [39] was used as the vector for cloning and expressing TEM alleles. This ~5.1-kb plasmid contains a tetracycline-resistance marker and replicates at ~10 copies per cell.

Media: LB-medium is 10g/L trypticase peptone, 5 g/L yeast extract and 10 g/L NaCl. LB-tetracycline medium is LB-medium containing 15 mg/L tetracycline and LB-kanamycin medium is LB-medium containing 50 mg/L kanamycin. Mueller Hinton (Merck) and Mueller Hinton II (BD) medium were prepared according to the manufacturers' instructions. SOC medium is 20 g/L bacto-tryptone and 5 g/L yeast extract with 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂ and 20 mM glucose. Solid media contained 16 g/L agar.

Recombinant methodology. Plasmids were prepared from overnight LB-tetracycline cultures, and purified using a GenEluteTM Plasmid Miniprep Kit (Sigma). TEM-1 (861 bp long) was amplified from pBR322 using the high-fidelity *Pfu* polymerase (Stratagene), sense primer P1 (GGGGGGTCATGAGTATTCAACATTTCCGTGTCG, *Bsp*HI site underlined, this enzyme cuts 1 bp upstream of TEM-1's start codon) and antisense primer

P2 (CCGAGCTCTTGGTCTGACAGTTACCAATGC, *SacI* site underlined, this enzyme cuts 17 bp downstream of TEM-1's stop-codon), using the following temperature cycle: 30' at 95°C, 30' at 61°C and 90' at 72°C for 30 cycles, followed by 72°C for 10 min. The resulting amplicon was digested with *Bsp*HI and *SacI* (New England Biolabs). Plasmid pACSE3 was digested with the same restriction enzymes and dephosphorylated with Calf Intestinal Phosphatase (New England Biolabs). Digested amplicons and vectors were purified using Sigma's GenElute™ PCR Clean-up Kit, ligated using T4 DNA Ligase (New England Biolabs), and transformed into DH5αE by electroporation. Specific mutations were introduced into TEM-1 using the QuickChange site-directed mutagenesis kit (Stratagene). Note that in this protocol TEM-1's promoter region is not part of the amplicon.

Creation of TEM-1 libraries. Mutant TEM alleles were generated by introducing random mutations using the Genemorph I and II Mutagenesis Kits (Stratagene). Since the former kit was unexpectedly taken out of production and replaced by the latter, we carried out the initial experiment (Table 1) using Genemorph I, but were forced to switch to Genemorph II for all other experiments. Since the error-prone polymerases in both kits differ only slightly in their mutational spectrum (see the Genemorph II manual, Stratagene), this switch has not significantly influenced the outcome of our experiments. Primers used for error-prone PCR were P3 (TCATCCGGCTCGTATAATGTGGA) and P4 (ACTCTCTTCCGGGCGCTATCAT), which flank the multiple cloning site of pACSE3. In order to make a broad exploration of the diversity of adaptive pathways, we varied the mutation rate (high rate in lines 1-6, and low rate in lines 7-12 of Table 1) and also introduced a simplified form of recombination in the initial experiment (in lines 4-6 and 9-

12). The mutation rate was manipulated by varying the effective number of replication cycles by the application of a lower amount of template DNA (see Text S1). Conditions were set to introduce on average ~ 2 (low mutation rate) or ~ 6 (high mutation rate) mutations per amplicon (0.06 and 565 plasmid template, respectively). The resulting amplicons were digested with *Bsp*HI and *Sac*I, ligated into pACSE3 and electroporated into DH5 α E. After recovery for 90 min in SOC medium at 37°C, the cells were diluted in 500 mL LB-tetracycline. An aliquot was taken out directly after mixing and plated onto LB-tetracycline agar to determine the library size. The remainder of the culture was incubated at 37°C overnight to amplify the library. Effective library sizes varied between $\sim 10^4$ and 10^6 transformants with an average of $\sim 6 \times 10^5$. Aliquots of the amplified libraries were stored in 10% glycerol at -80°C.

Recombination. In the first experiment, recombination between mutant TEM-1 alleles within a library was allowed in some lines (4-6 and 10-12) by digestion of the error-prone PCR amplicons with *Pvu*I. TEM-1 has a single *Pvu*I restriction site roughly in the middle of the sequence, allowing recombination via a single cross-over, as confirmed by the analysis of restriction markers. The truncated amplicons were ligated into pACSE3 via a single ligation step as described above.

Expression and selection. Expression of the TEM-1 allele in pACSE3 is under control of the *pTAC* promoter that is tightly regulated by the lac repressor, encoded by the *lacI* gene on pACSE3. Expression was induced by adding 50 μ M isopropyl- β -D-thiogalactopyranoside (IPTG), which was shown to mimic natural expression of TEM-1

[39]. For selection, a series of bottles containing 50 mL Mueller-Hinton medium (Merck) was inoculated with cefotaxime (Sigma, stock solution in 0.1M NaPO₄, pH 7.0) concentrations in two-fold increments, ranging from 0.0625 µg/mL, the MIC of wild-type TEM-1, to 1024 µg/mL. Each bottle was inoculated with a cell number approximately equal to 10 times the library size from the overnight amplified cultures. Cultures were incubated for 48 hours at 37°C. The culture that grew at the highest concentration of cefotaxime was plated on LB-tetracycline agar. The presumed clonal fixation of a single adaptive mutant in these 48 hour cultures [39] was confirmed by the sequence analysis of 10 randomly picked clones from a single culture (see Text S1). Therefore, the next day, a single colony was selected and grown overnight in LB-tetracycline. Plasmid from the overnight culture was isolated using GeneElute™ Plasmid Miniprep Kit (Sigma) and sequenced using BigDye™ (Perkin Elmer) or DYEnamic™ (AP-biotech) Terminator Cycle Sequence kits.

MIC assays. The Minimal Inhibitory Concentration (MIC) was determined from 150 µl cultures at a titre of 10⁵ cells/ mL in Mueller Hinton II medium containing 50 µM IPTG. A 150 µl solution of twofold serial dilutions of antibiotic in MH II was added to these cultures. Cultures were grown for 24 hours at 37°C, growth was determined by visual inspection, and MIC was defined as the lowest concentration of antibiotic that completely prevents visible growth. To exclude phenotypic variation in bacteria, plasmid was isolated from all selected clones and re-transformed into isogenic *E. coli* DH5αE cells prior to each MIC-assay. Ampicillin MICs were determined without the addition of IPTG, since this turned out to mask differences between different mutants tested.

Protein purification and thermal denaturation measurements. Measurements were performed essentially as earlier described [40]. The equation used to fit the row thermal denaturation was:

$$y = ((\alpha_U - q \cdot T) \cdot (1 - \exp((m_{N-U} \cdot (T - T_m)) / (-582)) / (1 - \exp((m_{N-U} \cdot (T - T_m)) / RT)))) + ((\alpha_N - p \cdot T) \cdot (1 - \exp((m_{N-U} \cdot (T - T_m)) / (-582)) / (1 - \exp((m_{N-U} \cdot (T - T_m)) / RT))))$$

Where α_N is the fluorescence of the native structure at $T = 25$ °C, p is a slope of fluorescence change of the native state, α_U is a fluorescence at $T = 80$ °C, q is a slope of fluorescence change of the unfolded state, and m_{N-U} is the slope of transition, $RT = -582$.

Kinetic measurements. The kinetic parameters k_{cat} and K_M were determined by non-linear regression fit to the Michaelis-Menten equation using the KaleidaGraph program (Synergy Software). Initial velocities were recorded with increasing substrate concentrations from $1/3 \cdot K_M$ to $3 \cdot K_M$. For ampicillin, hydrolysis of the β -lactam ring was monitored by loss of absorbance at 232nm ($\Delta\epsilon = 600 \text{ M}^{-1}\text{cm}^{-1}$), using a quartz plate (path of 0.5 cm) in a microtitre plate reader (bioTeck). The hydrolysis of cefotaxime was monitored by loss of absorbance at 264nm ($\Delta\epsilon = 6360 \text{ M}^{-1}\text{cm}^{-1}$). Because of the high initial absorbance, a quartz cell of 0.1 cm pathway was used for measurements at $\geq 250 \mu\text{M}$ cefotaxime. The readings in lower concentrations were performed in quartz plate in a plate reader (path of 0.5 cm).

Statistical analyses. Since MIC values are measured on a discontinuous scale (with two-fold increases in antibiotic concentration), non-parametric tests on differences in median MIC estimates were used.

Acknowledgements We thank B. Koopmanschap and A. Geerling for help with the experiments and D. Aanen, T. Bisseling, M. Camps, S. Elena, D. Rozen, L. Silverman, D. Weinreich and M. Zwart for comments on the manuscript.

References

1. Kondrashov FA, Kondrashov AS (2001) Multidimensional epistasis and the disadvantage of sex. *Proc Natl Acad Sci U S A* 98: 12089-12092.
2. Mani GS, Clarke BC (1990) Mutational order - a major stochastic process in evolution. *Proc R Soc Biol Sci Ser B* 240: 29-37.
3. de Visser JAGM, Lenski RE (2002) Long-term experimental evolution in *Escherichia coli*. XI. Rejection of non-transitive interactions as cause of declining rate of adaptation. *BMC Evol Biol* 2: -.
4. MacLean RC, Perron GG, Gardner A (2010) Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in *Pseudomonas aeruginosa*. *Genetics*.
5. Weinreich DM, Watson RA, Chao L (2005) Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. *Evolution* 59: 1165-1174.
6. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ (2007) Empirical fitness landscapes reveal accessible evolutionary paths. *Nature* 445: 383-386.
7. Weinreich DM, Chao L (2005) Rapid evolutionary escape by large populations from local fitness peaks is likely in nature. *Evolution* 59: 1175-1182.
8. de Visser JAGM, Park, S.-C. & Krug, J. (2009) Exploring the effect of sex on empirical fitness landscapes. *Am Nat* 174: s15-s30.

9. Weissman DB, Feldman MW, Fisher DS (2010) The rate of fitness-valley crossing in sexual populations. *Genetics*.
10. Povolotskaya IS, Kondrashov FA (2010) Sequence space and the ongoing expansion of the protein universe. *Nature* 465: 922-926.
11. Wichman HA, Badgett MR, Scott LA, Boulianne CM, Bull JJ (1999) Different trajectories of parallel evolution during viral adaptation. *Science* 285: 422-424.
12. Bollback JP, Huelsenbeck JP (2009) Parallel Genetic Evolution Within and Between Bacteriophage Species of Varying Degrees of Divergence. *Genetics* 181: 225-234.
13. Schoustra SE, Debets AJM, Slakhorst M, Hoekstra RF (2007) Mitotic recombination accelerates adaptation in the fungus *Aspergillus nidulans*. *PLoS Genetics* 3: e68.
14. Wood TE, Burke JM, Rieseberg LH (2005) Parallel genotypic adaptation: when evolution repeats itself. *Genetica* 123: 157-170.
15. Travisano M, Mongold JA, Bennett AF, Lenski RE (1995) Experimental Tests of the Roles of Adaptation, Chance, and History in Evolution. *Science* 267: 87-90.
16. Woods R, Schneider D, Winkworth CL, Riley MA, Lenski RE (2006) Tests of parallel molecular evolution in a long-term experiment with *Escherichia coli*. *Proc Natl Acad Sci U S A* 103: 9107-9112.
17. Blount ZD, Borland CZ, Lenski RE (2008) Historical contingency and the evolution of a key innovation in an experimental population of *Escherichia coli*. *Proc Natl Acad Sci U S A* 105: 7899-7906.
18. Stemmer WP (1994) Rapid evolution of a protein in vitro by DNA shuffling. *Nature* 370: 389-391.
19. Barlow M, Hall BG (2002) Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the TEM β -lactamase. *Genetics* 160: 823-832.
20. Bershtein S, Segal M, Bekerman R, Tokuriki N, Tawfik DS (2006) Robustness-epistasis link shapes the fitness landscape of a randomly drifting protein. *Nature* 444: 929-932.
21. Barlow M, Hall BG (2003) Experimental prediction of the natural evolution of antibiotic resistance. *Genetics* 163: 1237-1241.

22. Vakulenko SB, Geryk B, Kotra LP, Mobashery S, Lerner SA (1998) Selection and characterization of β -lactam- β -lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 β -lactamase gene. *Antimicrob Agents Chemother* 42: 1542-1548.
23. Hall BG (2002) Predicting evolution by in vitro evolution requires determining evolutionary pathways. *Antimicrob Agents Chemother* 46: 3035-3038.
24. Weinreich DM, Delaney NF, DePristo MA, Hartl DL (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. *Science* 312: 111-114.
25. Giakkoupi P, Tzelepi E, Tassios PT, Legakis NJ, Tzouveleki LS (2000) Detrimental effect of the combination of R164S with G238S in TEM-1 β -lactamase on the extended-spectrum activity conferred by each single mutation. *J Antimicrob Chemother* 45: 101-104.
26. Zacco M, Gherardi E (1999) The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 β -lactamase. *J Mol Biol* 285: 775-783.
27. Hecky J, Muller KM (2005) Structural perturbation and compensation by directed evolution at physiological temperature leads to thermostabilization of β -lactamase. *Biochemistry* 44: 12640-12654.
28. Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T (2010) Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β -lactamases. *J Mol Biol* 404: 832-846.
29. Kather I, Jakob RP, Dobbek H, Schmid FX (2008) Increased folding stability of TEM-1 β -lactamase by in vitro selection. *J Mol Biol* 383: 238-251.
30. Orenica MC, Yoon JS, Ness JE, Stemmer WPC, Stevens RC (2001) Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. *Nat Struct Biol* 8: 238-242.
31. Cantu C, Huang WZ, Palzkill T (1997) Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase. *J Biol Chem* 272: 29144-29150.
32. Salverda MLM, De Visser JAGM, Barlow M (2010) Natural evolution of TEM-1 β -lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiol Rev* 34: 1015-1036.

33. Huang WZ, Le QQ, Larocco M, Palzkill T (1994) Effect of Threonine-to-Methionine substitution at position 265 on structure and function of TEM-1 β -lactamase. *Antimicrob Agents Chemother* 38: 2266-2269.
34. Firth AE, Patrick WM (2005) Statistics of protein library construction. *Bioinformatics* 21: 3314-3315.
35. DePristo MA, Weinreich DM, Hartl DL (2005) Missense meanderings in sequence space: A biophysical view of protein evolution. *Nat Rev Genet* 6: 678-687.
36. Tokuriki N, Tawfik DS (2009) Stability effects of mutations and protein evolvability. *Curr Opin Struct Biol* 19: 596-604.
37. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ (2007) Empirical fitness landscapes reveal accessible evolutionary paths. *Nature* 445: 383-386.
38. Weinreich DM, Watson RA, Chao L (2005) Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. *Evolution* 59: 1165-1174.
39. Barlow M, Hall BG (2002) Predicting evolutionary potential: *In vitro* evolution accurately reproduces natural evolution of the TEM beta-lactamase. *Genetics* 160: 823-832.
40. Bershtein S, Goldin K, Tawfik DS (2008) Intense neutral drifts yield robust and evolvable consensus proteins. *J Mol Biol* 379: 1029-1044.
41. Ambler RP, Coulson AFW, Frere JM, Ghuysen JM, Joris B, et al. (1991) A standard numbering scheme for the class-A β -lactamases. *Biochem J* 276: 269-270.
42. Sutcliffe JG (1978) Nucleotide-Sequence of Ampicillin Resistance Gene of *Escherichia-Coli* Plasmid Pbr322. *Proc Natl Acad Sci U S A* 75: 3737-3741.
43. Fersht AR (1985) *Enzyme structure and mechanism*. New York: Freeman.

Figure legends

Figure 1: Cefotaxime MIC of selected TEM alleles. (A) Adaptation of TEM-1 β -lactamase towards improved hydrolysis of cefotaxime. Lines show changes in the average Minimal Inhibitory Concentration (MIC) of cefotaxime for the twelve lines shown in Table 1. Aberrant lines 3 and 4 are indicated with solid lines and open and closed triangles, respectively. **(B)** Increase in cefotaxime MIC for TEM-1 (bold line, the average of figure 1A) and mutants R164S (open diamonds, dashed line), A237T (diamonds, dashed line), R164S/ G238S (open squares) and A237T/ G238S (squares).

Tables

Table 1. Amino acid substitutions in evolved TEM-1 alleles

Pos. †	Amino acid substitution*											
	High mutation frequency						Low mutation frequency					
	No recombination			Recombination			No recombination			Recombination		
	1	2	3	4	5	6	7	8	9	10	11	12
10	V10I			<u>V10I</u>		<i>V10I</i>						
19		<i>F19I</i>				<u>F19C</u>		<u>F19L</u>				
33										V33I		
104	<i>E104K</i>	<i>E104K</i>			<i>E104K</i>	<i>E104K</i>		<i>E104K</i>	<i>E104K</i>	<i>E104K</i>	<i>E104K</i>	<i>E104K</i>
114												<i>T114M</i>
124											<i>S124G</i>	
145				<i>P145Q</i>								
149				T149A								
153	<u>H153L</u>											
155						<i>M155I</i>				M155I		
164			R164S									
167			<i>P167T</i>									
172				A172V								
175				<i>N175D</i>								
179				<i>D179G</i>								
182	M182T	M182T	<i>M182T</i>	M182T	M182T	M182T		M182T	M182T	<i>M182T</i>		
184							A184V					
188												<i>T188R</i>
191							R191H					
200							<i>T200S</i>					
201				L201I								
235				<i>S235T</i>								
237				A237T								
238	G238S	G238S			G238S	G238S	G238S	G238S	G238S	G238S	G238S	G238S
240			E240K				<i>E240K</i>					
249								<u>A249V</u>				
265				<i>T265M</i>			<i>T265M</i>				<i>T265M</i>	T265M
267			<u>G267A</u>									
271				<i>T271I</i>								
281		E281-										
Round	MIC value											
1	64	4	8	8	8	16	2	8	16	2	2	4
2	512	128	32	64	256	64	128	256	256	128	128	64
3	256	256	64	128	512	256	64	256	256	256	64	64

*Substitutions are shown as the TEM-1 amino acid according to the IUPAC single-letter code (left), the position in the protein [41] (middle), and the mutant amino acid (right).

†Position according to [42]. Substitutions found after the first round (and hence in all subsequent rounds) are in **bold**, those found after the second round are in *italic* and those found after the third are underlined. Note that mutations V33I and M155I in line 10 were no

longer present after round 2 and 3 and mutation V10I in line 1 was no longer present after round 3. The MIC value shown is the median value across three replicates (see Table S3 for replicate measurements).

Table 2. Amino acid substitutions in evolved TEM-mutants R164S and A237T

Pos.	R164S alleles					A237T alleles				
	1	2	3	4	5	1	2	3	4	5
10					<u>V10I</u>					
24	<i>F24C</i>									
27										<u>P27L</u>
38		<i>D38G</i>								
39							<i>Q39R</i>			
88				<i>Q88L</i>						
97					Y97F					
100		<i>N100K</i>								
104				E104K						E104K
124	S124R			<u>M129L</u>						
129										
163								D163V		
164	R164S	R164S	R164S	R164S	R164S	R164CY	R164S			R164H
164						<u>C164Y</u>				
165								<i>W165G</i>		
169									L169P	
173	<i>I173V</i>		<u>I173V</u>				<u>I173T</u>			
175										<i>N175Y</i>
180		<i>T180S</i>								
182						M182T		M182T	M182T	<i>M182T</i>
184				<u>A184T</u>						
188			<i>T188I</i>							
192							<u>K192N</u>			<i>K192E</i>
197	<i>E197K</i>									
201				<i>L201P</i>			<u>L201P</u>			
216				<i>V216I</i>						<u>V216I</u>
217										
224				A224V		<i>A224V</i>		<u>A217S</u>		
235	<i>S235T</i>							<u>A224V</u>		
237		<i>A237T</i>	<i>A237T</i>		<i>A237T</i>	<i>A237T</i>	<i>A237T</i>	<i>A237T</i>	<i>A237T</i>	<i>A237T</i>
240	E240K	E240K	E240K		E240K	E240K	E240K			
241		<i>R241H</i>			<i>R241H</i>					
247				<u>I247V</u>						
249				<u>A249V</u>						
256			<u>K256N</u>							
265		<i>T265M</i>								
267				<u>G267V</u>						
268					<u>S268G</u>					
278				<u>Q278R</u>						
291	<i>end291K</i>									
Round	MIC value									
1	4	8	4	16	8	4	32	1	8	4
2	16	64	32	16	64	32	32	8	8	64
3	16	32	32	16	128	64	32	16	16	64

See Table 1 for details. The substitutions present in the starting alleles and still present at the end of the experiment are in normal text.

Table 3. Amino acid substitutions in evolved TEM double-mutants R164S/ G238S and A237T/ G238S

Position	<i>Amino acid substitution</i>				
	1	2	3	4	5
38					D38V
39				Q39K	
42				<i>A42G</i>	
48	E48V				
49					L49M
104	E104K	E104K			<i>E104K</i>
111		<i>K111M</i>			
153		<i>H153R</i>	<u>H153Q</u>		
175					<u>N175D</u>
184	A184V	A184V	A184V	A184V	A184V
208		I208M	<u>I208M</u>		
213			A213P		
238	G238S	G238S	G238S	G238S	G238S
240			<u>E240K</u>	E240K	
265			T265M		
<i>Round</i>			<i>MIC values</i>		
1	32	32	8	64	8
2	64	128	8	128	32
3	32	128	128	128	32

See Table 1 for details. The substitutions present in the starting alleles (and still present at the end of the experiment) are in normal text.

Table 4. Amino acid substitutions in evolved TEM double-mutants R164S/ G238S and A237T/ G238S

Pos.	R164S/G238S alleles					Amino acid substitution		A237T/G238S alleles			
	1	2	3	4	5	1	2	3	4	5	
4						<u>S4N</u>					
7				<u>H7Q</u>							
16	<u>F16L</u>										
17		A17S									
21	<u>L21H</u>										
24								<u>F24S</u>			
27						<u>P27S</u>					
38					<i>D38V</i>						
47	I47V										
56				<u>I56T</u>							
60		<i>F60Y</i>									
92		<i>G92D</i>						G92D			
104		E104V	<i>E104K</i>	E104Q	<i>E104K</i>	<i>E104K</i>		<i>E104K</i>	<i>E104K</i>	<i>E104K</i>	
115						D115E					
120										<i>R120K</i>	
124										<i>S124N</i>	
153					<u>H153R</u>				H153R		
164	<u>S164R</u>	S164R	S164R	S164R	S164R			R164G			
174								<u>P174R</u>			
182	<i>M182T</i>			<i>M182T</i>		M182T	M182T				
184	<i>A184V</i>										
188			<u>T188K</u>								
192	<i>K192N</i>										
197				<u>E197K</u>							
198					<i>L198V</i>			<i>L198I</i>			
208	<u>I208K</u>										
224								<i>A224V</i>	<i>A224V</i>		
235								<u>S235T</u>			
237						<i>T237A</i>	<i>A237T</i>	<i>A237T</i>	<i>A237T</i>	<i>A237T</i>	
238	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	<i>G238S</i>	
240	E240K										
268								S268G			
275			<i>R275Q</i>						<i>R275Q</i>	R275L	
289						<u>H289Y</u>					
Round	MIC value										
1	2	4	1	2	1	2	4	4	1	2	
2	64	64	128	128	256	512	32	256	64	64	
3	512	64	128	512	256	512	32	128	64	64	

See Table 1 for details. The substitutions present in the starting alleles and still present at the end of the experiment are in normal text.

Table 5. MIC values and kinetic and stability parameters of TEM-1, single mutants R164S and G238S and double mutant R164S/G238S.


		TEM-1	R164S	G238S	R164S+G238S
Ampicillin	K_M (μM)	71±9	37±7	26±4	11±11
Ampicillin	k_{cat} (sec^{-1})	1857±97	75±25	42±1.5	7±3
Ampicillin	k_{cat}/K_M ($\text{M}^{-1}\text{sec}^{-1}$)	$2.6*10^7\pm0.5*10^7$	$2.0*10^6\pm0.8*10^6$	$1.4*10^6\pm0.28*10^6$	$0.9*10^6\pm0.5*10^6$
Ampicillin	MIC ($\mu\text{g}/\text{ml}$)*	4096	4096	1024	512
Cefotaxime	K_M (μM)	N.D.	536±51	403±126	578±26
Cefotaxime	k_{cat} (sec^{-1})	N.D.	2.5±0.1	50±3	2.6±0.1
Cefotaxime	k_{cat}/K_M ($\text{M}^{-1}\text{sec}^{-1}$)	$1.0*10^3\pm0.02*10^3$	$4.7*10^3\pm0.4*10^3$	$1.30*10^5\pm0.4*10^5$	$4.5*10^3\pm0.5*10^3$
Cefotaxime	MIC ($\mu\text{g}/\text{ml}$)*	0.06	0.5	1.0	0.125
	T_m ($^{\circ}\text{C}$) [†]	55±0.5	52±1.5	50	52±1
	<i>m</i> value	289±2.3	305±4.5	248±2.3	108±0.8

The kinetic were acquired *in vitro* with purified proteins. The T_m and *m* values (indicating the cooperativity of unfolding) were extracted from heat denaturation. N.D.; not determined. Errors shown are standard deviations. Because of the high TEM-1 levels under induction, MIC assays for ampicillin were determined without the addition of IPTG. For additional details see Supporting Information and Figures S2 and S3.

* Median value across three replicates (see Table S3).

† The error ranges for TEM-1 and mutants R164S and R164S+G238S were determined from two independent measurements with two different protein preparations; error ranges for the remaining variant are estimated to be within the same range.

A



B

